Acute Lymphoblastic Leukemia Neurocognitive Function Study

Neurocognitive Function in Children Treated for Acute Lymphoblastic Leukemia

Protocol Description

This Children’s Oncology Group observational study evaluates brain function in young patients receiving methotrexate in treatment for acute lymphoblastic leukemia (ALL). Learning about the long-term effects of methotrexate on learning skills and memory as well as evaluating the potential toxicity associated with the drug may help doctors plan cancer treatment.

Eligibility Criteria

Subject to certain exclusion criteria, the study is open to individuals of both genders, ages 1 to 17 with ALL who were treated with methotrexate as part of chemotherapy.
Males: Ages 1 to 17 years
Females: Ages 1 to 17 years

Approximately one year after their chemotherapy has ended, participants will undergo a single assessment that measures thinking, memory, attention and concentration. With parental permission, researchers will also conduct an optional imaging study of the brain using a type of MRI scan.
Visits: 1
Duration: Not applicable

Status: Open for Enrollment

Source(s) of Support
Children’s Oncology Group (Study AALL06N1)
National Cancer Institute

Additional Resources
Study Description at National Institutes of Health

Primary Investigator(s)

A. Kim Ritchey, MD

Contact Information

For additional information, please contact:
Jill Visnich

Last Update
February 17, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
February 17, 2014